Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Akeso Yönetim

Yönetim kriter kontrolleri 2/4

Akeso's CEO'su Michelle Xia, Mar2012 tarihinde atandı, in görev süresi 12.58 yıldır. in toplam yıllık tazminatı CN¥ 6.52M olup, şirket hissesi ve opsiyonları dahil olmak üzere 67% maaş ve 33% ikramiyelerden oluşmaktadır. şirketin hisselerinin 9.1% ine doğrudan sahiptir ve bu hisseler HK$ 5.40B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 4.9 yıldır.

Anahtar bilgiler

Michelle Xia

İcra Kurulu Başkanı

CN¥6.5m

Toplam tazminat

CEO maaş yüzdesi	67.0%
CEO görev süresi	12.6yrs
CEO sahipliği	9.1%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	4.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Michelle Xia'un ücretlendirmesi Akeso'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CN¥735m
Mar 31 2024	n/a	n/a	CN¥646m
Dec 31 2023	CN¥7m	CN¥4m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥409m
Dec 31 2022	CN¥5m	CN¥4m	-CN¥1b
Sep 30 2022	n/a	n/a	-CN¥1b
Jun 30 2022	n/a	n/a	-CN¥1b
Mar 31 2022	n/a	n/a	-CN¥1b
Dec 31 2021	CN¥7m	CN¥4m	-CN¥1b
Sep 30 2021	n/a	n/a	-CN¥1b
Jun 30 2021	n/a	n/a	-CN¥929m
Mar 31 2021	n/a	n/a	-CN¥983m
Dec 31 2020	CN¥7m	CN¥3m	-CN¥1b
Sep 30 2020	n/a	n/a	-CN¥870m
Jun 30 2020	n/a	n/a	-CN¥703m
Mar 31 2020	n/a	n/a	-CN¥492m
Dec 31 2019	CN¥2m	CN¥1m	-CN¥282m

Tazminat ve Piyasa: Michelle 'nin toplam tazminatı ($USD 915.97K ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 689.23K ).

Tazminat ve Kazançlar: Michelle şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Michelle Xia (57 yo)

12.6yrs

Görev süresi

CN¥6,524,000

Tazminat

Dr. Yu Xia, Ph D., also known as Michelle, is CEO & President of Akeso Biopharma, Inc. Dr. Xia is Founder of Akeso, Inc. Dr. Xia is CEO, President & Chairwoman of Akeso, Inc. from March 19, 2012. She has b...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yu Xia	Founder	12.6yrs	CN¥6.52m	9.1% HK$ 5.5b
Baiyong Li	Co-Founder	12.6yrs	CN¥5.02m	6.2% HK$ 3.7b
Zhongmin Wang	Co-Founder	no data	CN¥3.60m	5.22% HK$ 3.1b
Peng Zhang	Co-Founder	no data	Veri yok	Veri yok
Bing Wang	Chief Financial Officer	less than a year	Veri yok	Veri yok
Xinfeng Zhang	Senior Vice President	4.3yrs	Veri yok	Veri yok
Wenjun Shi	Senior Vice President	4.2yrs	Veri yok	Veri yok
Mingxiu Hu	Senior Vice President	2.8yrs	Veri yok	Veri yok
Charlie Zhang	Senior Vice President	1.8yrs	Veri yok	Veri yok
Jing Min	Senior Vice President	1.8yrs	Veri yok	Veri yok
Wai Yan Leung	Company Secretary	2.2yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: 9926 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yu Xia	Founder	12.6yrs	CN¥6.52m	9.1% HK$ 5.5b
Baiyong Li	Co-Founder	4.9yrs	CN¥5.02m	6.2% HK$ 3.7b
Zhongmin Wang	Co-Founder	4.9yrs	CN¥3.60m	5.22% HK$ 3.1b
Peng Zhang	Co-Founder	less than a year	Veri yok	Veri yok
Bo Tan	Independent Non-Executive Director	no data	CN¥317.00k	Veri yok
Ronggang Xie	Non-Executive Director	4.2yrs	Veri yok	Veri yok
Yan Xu	Independent Non-Executive Director	no data	CN¥319.00k	Veri yok
Junwen Zeng	Independent Non-Executive Director	no data	CN¥317.00k	Veri yok

4.9yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 9926 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.9 yıldır).

Akeso Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Akeso, Inc. Announces Appointment of Bing C. Wang as Chief Financial Officer

Akeso, Inc. Announces Change of Directors

Akeso, Inc. Announces Change of Directors

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Founder recently sold HK$96m worth of stock

Co-Founder recently sold HK$4.4m worth of stock

Recent updates

Akeso Biopharma Announces Positive Results in Progression-Free Survival (PFS) and Overall Survival (OS) from Its Phase 3 Clinical Study

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population

Akeso, Inc. Secures Approval from China’s National Medical Products Administration for Ebronucimab, Expanding Treatment Options for Hypercholesterolemia

Akeso's Ivonescimab Plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety At ESMO 2024

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso, Inc. to Report Q2, 2024 Results on Aug 28, 2024

Akeso, Inc. Announces Ivonescimab (Pd-1/Vegf) Received Priority Review from China's Nmpa for First-Line Treatment of Pd-L1 Positive Nsclc

Akeso, Inc. Announces That the First Patient Enrolled in the US Phase 2 Combination Therapy of it's Ligufalimab with Azacitidine for Myelodysplastic Syndrome

Akeso's Sbla for Ivonescimab in 1L Treatment of Pd-L1 Positive Nsclc Accepted by NMPA

Akeso, Inc. Announces Appointment of Bing C. Wang as Chief Financial Officer

New major risk - Share price stability

Akeso, Inc. Announces Change of Directors

Akeso, Inc. Announces Change of Directors

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival

New minor risk - Share price stability

Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection

Investor sentiment deteriorates as stock falls 24%

Full year 2023 earnings released: EPS: CN¥2.42 (vs CN¥1.42 loss in FY 2022)

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

New minor risk - Shareholder dilution

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Full year 2023 earnings released: EPS: CN¥2.42 (vs CN¥1.42 loss in FY 2022)

Investor sentiment improves as stock rises 15%

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Akeso, Inc. Announces Innovative Clinical Development Roadmap

Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer

Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023

Akeso Publishes Results from Three Investigator-Initiated Trials

Founder recently sold HK$96m worth of stock

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Co-Founder recently sold HK$4.4m worth of stock

Investor sentiment improves as stock rises 17%

Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody

Akeso Announces the Publication of the Phase 1a/1b First-In-Human Study

Akeso, Inc. Announces Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

Akeso, Inc. Announces FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

First half 2023 earnings released: EPS: CN¥3.02 (vs CN¥0.77 loss in 1H 2022)

New major risk - Revenue and earnings growth

Akeso Inc. Announces Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC

Akeso, Inc. Announces the National Medical Products Administration Accepts the New Drug Application for the Ebdarokimab Injection (IL-12/IL-23 Monoclonal Antibody, AK101)

Akeso Inc. Announces First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-Line Treatment of Squamous NSCLC

Akeso, Inc. to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Akeso, Inc., Annual General Meeting, Jun 28, 2023

NMPA Accepts Akeso's Ebronucimab (PCSK9 ) Marketing Application in Two Cardiovascular Indications

No longer forecast to breakeven

Full year 2022 earnings released: CN¥1.42 loss per share (vs CN¥1.32 loss in FY 2021)

Forecast to breakeven in 2023

Akeso, Inc. Announces China NMPA Approved Anniko (Penpulimab) for First-Line Treatment of Locally Advanced or Metastatic Squamous NSCLC

Akeso Inc. Announces JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) Mechanism Shows Promising Antitumor Efficacy and Favorable Safety Profile

Forecast to breakeven in 2023

No longer forecast to breakeven

Less than half of directors are independent

Akeso, Inc. Announces Ivonescimab Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China

Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC

Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022

No longer forecast to breakeven

Akeso's Ivonescimab (PD-1/VEGF BsAbs) Granted Breakthrough Therapy Designation by China NMPA for the Treatment of Advanced NSCLC

Akeso, Inc. Develops Combination Therapies Based on Its PD-1 BsAbs, Ivonescimab (PD-1/VEGF) in Combination with Drebuxelimab (CD73) Approved for a Clinical Trial on Treating Advanced Solid Tumors

Akeso, Inc. Announces Commencement of Phase Ib/II clinical trial